Could a single chemo drug beat the standard doublet for some ovarian cancers?
NCT ID NCT07401654
First seen Feb 14, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This study compares a single chemotherapy drug (paclitaxel) against the standard two-drug combo (paclitaxel plus carboplatin) as initial treatment before surgery for advanced ovarian cancer. It includes 60 women whose tumors have a high level of the PARK2 gene, which may make them more sensitive to paclitaxel. The goal is to see if the single drug can be as effective while causing fewer side effects and delaying platinum exposure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.